301 related articles for article (PubMed ID: 38027003)
41. Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database.
Zhang S; Wang Y; Qi Z; Tong S; Zhu D
Int J Clin Pharm; 2024 Apr; 46(2):471-479. PubMed ID: 38245664
[TBL] [Abstract][Full Text] [Related]
42. A real-world pharmacovigilance analysis of the FDA adverse event reporting system events for polatuzumab vedotin.
Xu Z; Huang D; Liu Q; Liu S; Liu J; Wang H; Shen Z
Expert Opin Drug Saf; 2024 May; ():1-9. PubMed ID: 38695550
[TBL] [Abstract][Full Text] [Related]
43. A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system.
Fang Z; Xu Z; Zhu W; Yu M; Ji C
Front Pharmacol; 2023; 14():1101861. PubMed ID: 37342589
[No Abstract] [Full Text] [Related]
44. Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database.
Wu X; Zhang L; Huang H; Huang L; Lu X; Wang Z; Xiao J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):422-434. PubMed ID: 37164926
[TBL] [Abstract][Full Text] [Related]
45. Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system.
Li Y; Wang X; Liao Y; Zeng Y; Lin W; Zhuang W
BMC Infect Dis; 2024 May; 24(1):446. PubMed ID: 38724914
[TBL] [Abstract][Full Text] [Related]
46. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.
Liu L; Chen J; Wang L; Chen C; Chen L
Front Endocrinol (Lausanne); 2022; 13():1043789. PubMed ID: 36568085
[TBL] [Abstract][Full Text] [Related]
47. Post-marketing safety concerns of sotorasib: A disproportionality analysis based on FDA adverse event reporting system.
Ding Y; Su H; Shu Y; Chen J
Heliyon; 2024 May; 10(9):e30437. PubMed ID: 38726179
[TBL] [Abstract][Full Text] [Related]
48. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
[TBL] [Abstract][Full Text] [Related]
49. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
[TBL] [Abstract][Full Text] [Related]
50. Analysis of Inclisiran in the US FDA Adverse Event Reporting System (FAERS): a focus on overall patient population and sex-specific subgroups.
He Y; Guan X; Zhang Y; Zhu Z; Zhang Y; Feng Y; Li X
Expert Opin Drug Saf; 2024 May; ():1-9. PubMed ID: 38676389
[TBL] [Abstract][Full Text] [Related]
51. A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor.
Pan Y; Wang Y; Zheng Y; Chen J; Li J
Front Pharmacol; 2024; 15():1251961. PubMed ID: 38655177
[TBL] [Abstract][Full Text] [Related]
52. Electrolyte disorders induced by six multikinase inhibitors therapy for renal cell carcinoma: a large-scale pharmacovigilance analysis.
She X; Yin D; Guo Q; Tang Y; Wang S; Wang X
Sci Rep; 2024 Mar; 14(1):5592. PubMed ID: 38454105
[TBL] [Abstract][Full Text] [Related]
53. Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database.
Zhu H; Qu Y; Du Z; Zhou Q; Shen Y; Jiang Y; Zhou Z; Zhou H
J Affect Disord; 2024 Feb; 347():45-50. PubMed ID: 37992768
[TBL] [Abstract][Full Text] [Related]
54. Pregnancy-related adverse events associated with statins: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS).
Wu T; Shi Y; Zhu B; Li D; Li Z; Zhao Z; Zhang Y
Expert Opin Drug Saf; 2024 Mar; 23(3):313-321. PubMed ID: 37612600
[TBL] [Abstract][Full Text] [Related]
55. Post-marketing safety concerns with nirmatrelvir: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
Zhuang W; Xu J; Wu Y; Yang J; Lin X; Liao Y; Wan J; Weng L; Lin W
Br J Clin Pharmacol; 2023 Sep; 89(9):2830-2842. PubMed ID: 37170890
[TBL] [Abstract][Full Text] [Related]
56. Liver injury due to endothelin receptor antagonists: a real-world study based on post-marketing drug monitoring data.
Dong S; Guo X; Wang H; Sun C
Ther Adv Respir Dis; 2024; 18():17534666231223606. PubMed ID: 38179676
[TBL] [Abstract][Full Text] [Related]
57. Potential adverse events associated with sphingosine-1-phosphate (S1P) receptor modulators in patients with multiple sclerosis: an analysis of the FDA adverse event reporting system (FAERS) database.
Yang X; Yan Y; Liu S; Wang Z; Feng X
Front Pharmacol; 2024; 15():1376494. PubMed ID: 38846098
[TBL] [Abstract][Full Text] [Related]
58. Adverse Event Profile Differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: A Real-world, Pharmacovigilance Study.
Liu F; Yin G; Xue S; Rehman FU; Liao D; Pan Y
J Cancer; 2023; 14(17):3275-3284. PubMed ID: 37928419
[No Abstract] [Full Text] [Related]
59. Data mining and safety analysis of avatrombopag: a retrospective pharmacovigilance study based on the US food and drug administration's adverse event reporting system.
Zhu H; Wu M
Sci Rep; 2024 May; 14(1):11262. PubMed ID: 38760419
[TBL] [Abstract][Full Text] [Related]
60. A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database.
Yang H; Wan Z; Chen M; Zhang X; Cui W; Zhao B
Expert Opin Drug Metab Toxicol; 2023 Apr; 19(4):217-223. PubMed ID: 37243615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
